Literature DB >> 8486734

Assembly of vaccinia virus: role of the intermediate compartment between the endoplasmic reticulum and the Golgi stacks.

B Sodeik1, R W Doms, M Ericsson, G Hiller, C E Machamer, W van 't Hof, G van Meer, B Moss, G Griffiths.   

Abstract

Vaccinia virus, the prototype of the Poxviridae, is a large DNA virus which replicates in the cytoplasm of the host cell. The assembly pathway of vaccinia virus displays several unique features, such as the production of two structurally distinct, infectious forms. One of these, termed intracellular naked virus (INV), remains cells associated while the other, termed extracellular enveloped virus (EEV), is released from the cell. In addition, it has long been believed that INVs acquire their lipid envelopes by a unique example of de novo membrane biogenesis. To examine the structure and assembly of vaccinia virus we have used immunoelectron microscopy using antibodies to proteins of different subcellular compartments as well as a phospholipid analysis of purified INV and EEV. Our data are not consistent with the de novo model of viral membrane synthesis but rather argue that the vaccinia virus DNA becomes enwrapped by a membrane cisterna derived from the intermediate compartment between the ER and the Golgi stacks, thus acquiring two membranes in one step. Phospholipid analysis of purified INV supports its derivation from an early biosynthetic compartment. This unique assembly process is repeated once more when the INV becomes enwrapped by an additional membrane cisterna, in agreement with earlier reports. The available data suggest that after fusion between the outer envelope and the plasma membrane, mature EEV is released from the cell.

Entities:  

Mesh:

Year:  1993        PMID: 8486734      PMCID: PMC2119557          DOI: 10.1083/jcb.121.3.521

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  65 in total

1.  THE CHEMICAL COMPOSITION OF VACCINIA VIRUS.

Authors:  H T ZWARTOUW
Journal:  J Gen Microbiol       Date:  1964-01

2.  Vaccinia virus reexamined: development and release.

Authors:  C Morgan
Journal:  Virology       Date:  1976-08       Impact factor: 3.616

3.  Biogenesis of vaccinia: isolation and characterization of a surface component that elicits antibody suppressing infectivity and cell-cell fusion.

Authors:  W Stern; S Dales
Journal:  Virology       Date:  1976-11       Impact factor: 3.616

4.  Rifampin and vaccinia DNA.

Authors:  M Esteban
Journal:  J Virol       Date:  1977-02       Impact factor: 5.103

5.  Acyl bis(monoacylglycero)phosphate, assumed to be a marker for lysosomes, is a major phospholipid of vaccinia virions.

Authors:  G Hiller; H Eibl; K Weber
Journal:  Virology       Date:  1981-09       Impact factor: 3.616

6.  Immunochemistry on ultrathin frozen sections.

Authors:  K T Tokuyasu
Journal:  Histochem J       Date:  1980-07

7.  Glycerophospho-(N-acyl)-ethanolamine lipids in degenerating BHK cells.

Authors:  P Somerharju; O Renkonen
Journal:  Biochim Biophys Acta       Date:  1979-04-27

8.  Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia.

Authors:  L G Payne
Journal:  J Gen Virol       Date:  1980-09       Impact factor: 3.891

9.  Polypeptide composition of extracellular enveloped vaccinia virus.

Authors:  L Payne
Journal:  J Virol       Date:  1978-07       Impact factor: 5.103

10.  Mechanism of vaccinia virus release and its specific inhibition by N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine.

Authors:  L G Payne; K Kristenson
Journal:  J Virol       Date:  1979-11       Impact factor: 5.103

View more
  161 in total

1.  Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus.

Authors:  M I Vázquez; M Esteban
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Regulation of vaccinia virus morphogenesis: phosphorylation of the A14L and A17L membrane proteins and C-terminal truncation of the A17L protein are dependent on the F10L kinase.

Authors:  T Betakova; E J Wolffe; B Moss
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.

Authors:  W H Zhang; D Wilcock; G L Smith
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Entry of the two infectious forms of vaccinia virus at the plasma membane is signaling-dependent for the IMV but not the EEV.

Authors:  J K Locker; A Kuehn; S Schleich; G Rutter; H Hohenberg; R Wepf; G Griffiths
Journal:  Mol Biol Cell       Date:  2000-07       Impact factor: 4.138

5.  Characterization of the vaccinia virus H3L envelope protein: topology and posttranslational membrane insertion via the C-terminal hydrophobic tail.

Authors:  F G da Fonseca; E J Wolffe; A Weisberg; B Moss
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 6.  Directed egress of animal viruses promotes cell-to-cell spread.

Authors:  David C Johnson; Mary T Huber
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera.

Authors:  B M Ward; B Moss
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Relationship between vaccinia virus intracellular cores, early mRNAs, and DNA replication sites.

Authors:  Massimo Mallardo; Edward Leithe; Sibylle Schleich; Norbert Roos; Laura Doglio; Jacomine Krijnse Locker
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  The vaccinia virus A9L gene encodes a membrane protein required for an early step in virion morphogenesis.

Authors:  W W Yeh; B Moss; E J Wolffe
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

10.  Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells.

Authors:  Juan Carlos Gallego-Gómez; Cristina Risco; Dolores Rodríguez; Pilar Cabezas; Susana Guerra; José L Carrascosa; Mariano Esteban
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.